SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back


National Association for Continuing Education
Speaker
Jacob O. Levitt, MD, FAAD
Professor
Vice Chair, Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Moderator
Brad P. Glick, DO, MPH, FAAD
Director, South Florida Psoriasis Treatment Centers
Clinical Assistant Professor of Dermatology
FIU Herbert Wertheim College of Medicine
Miami, FL

Title
: Pemphigus Vulgaris: Practice Pearls and Therapeutic Updates
Activity/Course #:
: NCME383
Cost:
: Free
Release/Start Date:
: Jul 01 2019
Expiration Date:
: Jun 30 2020
Topics:
: Dermatology
Target Audience:
: Dermatologists
Format:
: Webcast
Estimated Time To Complete CME Activity:
: 1.0 Hour
Credit(s):
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.50 pharmacology hour(s)
Hardware/Software Requirements:
Program Summary
Pemphigus vulgaris is a potentially fatal autoimmune disease mediated by circulating desmoglein-reactive autoantibodies directed against keratinocyte cell surfaces. The disease is characterized clinically by blisters and erosions of the skin and mucous membranes, and histologically by acantholysis. This activity will examine the clinical presentation and evaluation of pemphigus vulgaris, the data on existing and emerging therapies, and how to optimize treatment based on clinical presentation.

This webcast was recorded live at the Conversations in Dermatology 2019 and is being used with the permission of the presenters.

Learning Objectives
 
After completing this program participants should be able to:
  1. Describe the clinical presentation and evaluation of pemphigus vulgaris
  2. Discuss the data on established and emerging therapies for pemphigus vulgaris
  3. Optimize treatment strategies for pemphigus vulgaris based on clinical presentation
How to obtain the CME Certificate
  1. Register for the course at www.naceonline.com.
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 60% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1 contact hour of continuing education which includes 0.50 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Speaker
Dr. Levitt is a consultant for Novartis. He also serves on advisory boards for Janssen, Biofrontera, Abbvie and Corrona, LLC; and is a principal investigator for Corrona, LLC.

Moderator
Dr. Glick serves on the speaker’s bureau for SunPharma, Abbvie, Janssen, Celgene, Lilly, Novartis Pharmaceuticals Corporation, Ortho Dermatologics, Sanofi Regeneron, Dermira, Pfizer, Dermavant, and Sanofi Genzyme. He is also an advisor for Dermavant, Pfizer, Sanofi Genzyme, Dermira, Novartis, Lilly, SunPharma, Celgene and Abbvie; and an investigator for Abbvie, Celgene, Dermavant and ChemoCentryx.

Activity Planning Committe
Gregg Sherman, MD, has no relationships to disclose.

Josh Kilbridge, Medical Writer, has no relationships to disclose.

Michelle Frisch, MPH, has no relationships to disclose.

Daniela Hiedra, BA, has no relationships to disclose.

Sandy Bihlmeyer, MEd, has no relationships to disclose.
Commercial Support
This educational activity is supported by an educational grant from Genentech